# Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

> **NCT06109441** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AltruBio Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** ALTB-268

## Key facts

- **NCT ID:** NCT06109441
- **Lead sponsor:** AltruBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2026-03-05
- **Final completion:** 2028-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109441, "Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06109441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*